mRNA Therapy With Immunotherapy Cuts Melanoma Recurrence Risk by 49 Percent
A five-year follow-up of a phase 2b trial found the combination reduced recurrence or death compared with immunotherapy alone. The therapy is now in phase 3 testing for several cancers.
Fox NewsA personalized mRNA therapy combined with the immunotherapy drug pembrolizumab reduced the risk of melanoma recurrence or death by 49 percent after five years compared with pembrolizumab alone. The phase 2b KEYNOTE-942 study followed 157 patients with high-risk stage 3 or 4 melanoma whose tumors had been removed by surgery.
Participants were divided into two groups, with one receiving the mRNA therapy plus pembrolizumab and the other receiving pembrolizumab only.
Researchers reported that the benefit in the combination group remained sustained and durable over the five-year period. The therapy is created from mutations found in each patient’s own tumor to train the immune system to recognize and attack remaining cancer cells.
The most common side effects were fatigue, injection-site pain, chills, fever, and headache. Researchers stated the vaccine was well-tolerated, produced no new long-term safety concerns, and caused no severe vaccine-related adverse events.
The combination is currently being tested in a phase 3 trial called INTerpath across several hard-to-treat cancers. Company statements noted the data support continued investment in the mRNA platform for oncology applications.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
France 24WHO Reports 330 Confirmed Ebola Cases and 49 Deaths as Suspected Tally Falls to 116
The World Health Organization on Tuesday lowered its count of suspected Ebola cases from 906 to 116 after testing ruled out other illnesses. Confirmed cases stand at 330 across the Democratic Republic of Congo and Uganda.
Ebola Response Expands in Eastern DRC Despite Equipment and Tracing Challenges
Dr. Abdou Sebushishe of the International Medical Corps told CNN that efforts to contain the outbreak are growing while protective gear, contact tracing, and public trust remain limited.
The Hill**Judge Temporarily Blocks NSF Supercomputer Transfer from NCAR**
A federal judge issued a preliminary injunction blocking the transfer of a supercomputer used for climate and weather research. The ruling preserves operations at the National Center for Atmospheric Research in Boulder pending further review.